Breaking News, Trials & Filings

JHL Biotech Receives NMPA Approval

For Phase I & Phase III clinical trial applications for a proposed bevacizumab biosimilar, JHL1149, to treat forms of cancer

JHL Biotech announced that the National Medical Products Administration of the PRC (NMPA) has approved the company’s Phase I and Phase III Clinical Trial Application for a proposed bevacizumab biosimilar, JHL1149, to treat several forms of cancer, including advanced non-squamous non-small-cell lung cancer (NSCLC), metastatic colorectal cancer, metastatic kidney cancer, advanced cervical cancer and recurrent ovarian cancer.  JHL’s China NMPA Phase III trial approval together with ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters